Skip to content
DataLookout
Menu

CANDLENCT07747389

A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Study completion pushed from Sep 20, 2029 to Oct 23, 2029
    • Start date pushed from Oct 20, 2026 to Nov 11, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change from DB Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Week 6
Timeframe: DB Baseline (Day 1) up to Week 6

Secondary (3)

Change from DB Baseline in Clinical Global Impression-Severity (CGI-S) Score to Week 6
Change from DB Baseline in MADRS Total Score to Week 2
Change from DB Baseline in MADRS Total Score to Week 1

Arms and interventions

Lumateperone: Dose 1Experimental

Eligible participants will receive dose 1 of lumateperone once daily starting on Day 1 of Double-blind (DB) treatment period for up to 6 weeks. At Visit Week 6, participants who completed DB Treatment Period, may have the option to roll over into an open-label (OL) treatment period to receive dose 1 or dose 2 of lumateperone for up to 24 weeks.

Lumateperone: Dose 2Experimental

Eligible participants will receive dose 2 of lumateperone once daily starting on Day 1 of DB treatment period for up to 6 weeks. At Visit Week 6, participants who completed DB Treatment Period, may have the option to roll over into an OL treatment period to receive dose 1 or dose 2 of lumateperone for up to 24 weeks.

PlaceboPlacebo comparator

Eligible participants will receive placebo once daily starting on Day 1 of DB treatment period for up to 6 weeks. At Visit Week 6, participants who complete the DB treatment period, may have the option to participate in OL treatment period to receive dose 1 or dose 2 of lumateperone for up to 24 weeks.

Drugs: Lumateperone, Placebo